Grey matter atrophy in Parkinson’s disease with long-duration response
Objective: Aim of the study is to investigate neuroanatomical correlates of Long-Duration Response using structural magnetic resonance imaging (MRI) and voxel-based morphometry analysis. Background: Parkinson…Visual assessment of dopamine transporter imaging in normal pressure hydrocephalus
Objective: We aimed to investigate detailed analysis for striatal dopaminergic depletion in idiopathic normal pressure hydrocephalus (iNPH) with visual assessment. Background: Variable degree of parkinsonism…Neuronal Network Underlying Speech Difficulties in Parkinson’s Disease
Objective: We aimed to investigate whether speech difficulties are associated with changes in cortical thickness. Background: Speech difficulties are a common debilitating feature of Parkinson’s…Distributed Global Functional Connectivity Networks Predict Responsiveness to L-DOPA and Subthalamic Deep Brain Stimulation
Objective: To investigate global resting-state functional connectivity (rsFC) patterns associated with response to L-DOPA and to subthalamic nucleus (STN) deep brain stimulation (DBS) in patients…Comparison of Current DBS Platforms in the United States
Objective: To compare and contrast the currently available deep brain stimulation (DBS) platforms in the United States, their technical features, capabilities and practicality of usage.…Unilateral Leg Freezing in Moyamoya Syndrome
Objective: To report unilateral leg freezing in a patient with moyamoya syndrome. Background: Angiographic moyamoya is characterized by severe bilateral distal carotid stenosis with “puff-of-smoke”…Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial
Objective: To evaluate the efficacy of PRM in sleep disorders of patients with PD was investigated. Background: Sleep disorders are highly prevalent in patients with…Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease
Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions
Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results
Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…
- « Previous Page
- 1
- …
- 198
- 199
- 200
- 201
- 202
- …
- 405
- Next Page »